Patents by Inventor Gavin Whitlock

Gavin Whitlock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF
    Publication number: 20250145597
    Abstract: Provided are compounds of the Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
    Type: Application
    Filed: October 23, 2024
    Publication date: May 8, 2025
    Inventors: Matthew H. Daniels, Kenneth W. Duncan, Brian Andrew Sparling, Young-tae Lee, Jennifer Castro, Scott Ribich, Ernest Allen Sickmier, Andrew Stewart Tasker, James Edward John Mills, Gavin Whitlock, Andrew J. Jennings
  • 4-(2-PYRAZOLO[3,4-B]PYRIDINE-5-YL)ETHYNYL-2-PYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS
    Publication number: 20250129068
    Abstract: The invention provides compounds of formula: Wherein the substituents are as set out in further detail in the specification. The compounds are potent inhibitors of GCN2 and they have excellent pharmacokinetic properties. The compounds are useful for the treatment or prevention of a variety of conditions, particularly cancer. The invention further provides pharmaceutical compositions comprising the compounds of the invention and uses of the compounds and the compositions.
    Type: Application
    Filed: December 13, 2022
    Publication date: April 24, 2025
    Applicant: IP2IPO INNOVATIONS LIMITED
    Inventors: Gavin WHITLOCK, Matthew FUCHTER
  • Inhibitors of RNA helicase DHX9 and uses thereof
    Patent number: 12233065
    Abstract: Provided are compounds of the Formula (IVB): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
    Type: Grant
    Filed: March 28, 2024
    Date of Patent: February 25, 2025
    Assignee: ACCENT THERAPEUTICS, INC.
    Inventors: Matthew H. Daniels, Kenneth W. Duncan, Brian Andrew Sparling, Andrew Stewart Tasker, Gavin Whitlock
  • Disubstituted Pyrimidine Compounds for Ketohexokinase Inhibition
    Publication number: 20240409530
    Abstract: Disclosed herein are methods of inhibiting ketohexokinase (KHK) in a biological sample or subject, and of treating or preventing diseases or disorders (e.g., diseases or disorders associated with KHK dysregulation), comprising administering to said biological sample or subject an effective amount of a compound represented by Formula I or a compound of Table A, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 12, 2024
    Publication date: December 12, 2024
    Inventors: Gavin Whitlock, Paul Glossop, Timothy P. Rolph, Erik J. Tillman
  • Inhibitors of RNA helicase DHX9 and uses thereof
    Patent number: 12162867
    Abstract: Provided are compounds of the Formula (IIB): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
    Type: Grant
    Filed: March 28, 2024
    Date of Patent: December 10, 2024
    Assignee: ACCENT THERAPEUTICS, INC.
    Inventors: Matthew H. Daniels, Kenneth W. Duncan, Brian Andrew Sparling, Andrew Stewart Tasker, Gavin Whitlock
  • INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF
    Publication number: 20240316047
    Abstract: Provided are compounds of the Formula (IVB): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
    Type: Application
    Filed: March 28, 2024
    Publication date: September 26, 2024
    Inventors: Matthew H. Daniels, Kenneth W. Duncan, Brian Andrew Sparling, Andrew Stewart Tasker, Gavin Whitlock
  • INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF
    Publication number: 20240279210
    Abstract: Provided are compounds of the Formula (IIB): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
    Type: Application
    Filed: March 28, 2024
    Publication date: August 22, 2024
    Inventors: Matthew H. Daniels, Kenneth W. Duncan, Brian Andrew Sparling, Andrew Stewart Tasker, Gavin Whitlock
  • 4-ethynylpyridine derivatives useful as GCN2 inhibitors
    Patent number: 11945799
    Abstract: The invention provides compounds of formula I, wherein the substituents are as set out in further detail in the specification. The compounds are potent inhibitors of GCN2 and they have excellent pharmacokinetic properties. The compounds are useful for the treatment or prevention of a variety of conditions, particularly cancer. The invention further provides pharmaceutical compositions comprising the compounds of the invention and uses of the compounds and the compositions.
    Type: Grant
    Filed: March 28, 2023
    Date of Patent: April 2, 2024
    Assignee: IP2IPO INNOVATIONS LIMITED
    Inventors: Gavin Whitlock, Matthew Fuchter
  • 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS
    Publication number: 20230271939
    Abstract: The invention provides compounds of formula I, wherein the substituents are as set out in further detail in the specification. The compounds are potent inhibitors of GCN2 and they have excellent pharmacokinetic properties. The compounds are useful for the treatment or prevention of a variety of conditions, particularly cancer. The invention further provides pharmaceutical compositions comprising the compounds of the invention and uses of the compounds and the compositions.
    Type: Application
    Filed: June 9, 2021
    Publication date: August 31, 2023
    Applicant: IP2IPO INNOVATIONS LIMITED
    Inventors: Gavin WHITLOCK, Matthew FUCHTER
  • 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS
    Publication number: 20230250082
    Abstract: The invention provides compounds of formula I, wherein the substituents are as set out in further detail in the specification. The compounds are potent inhibitors of GCN2 and they have excellent pharmacokinetic properties. The compounds are useful for the treatment or prevention of a variety of conditions, particularly cancer. The invention further provides pharmaceutical compositions comprising the compounds of the invention and uses of the compounds and the compositions.
    Type: Application
    Filed: March 28, 2023
    Publication date: August 10, 2023
    Applicant: IP2IPO INNOVATIONS LIMITED
    Inventors: Gavin WHITLOCK, Matthew FUCHTER
  • 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS
    Publication number: 20220251041
    Abstract: The present invention relates to novel compounds and method for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (II) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R8, R9, R10, R12, Z, Y and m are as defined herein.
    Type: Application
    Filed: March 31, 2022
    Publication date: August 11, 2022
    Inventors: Alison Jones, Mark Kemp, Martin Stockley, Karl Gibson, Gavin Whitlock
  • 1-cyano-pyrrolidine compounds as USP30 inhibitors
    Patent number: 11390584
    Abstract: The present invention relates to novel compounds and method for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (II) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R8, R9, R10, Z, Y and m are as defined herein.
    Type: Grant
    Filed: February 12, 2020
    Date of Patent: July 19, 2022
    Assignee: Mission Therapeutics Limited
    Inventors: Alison Jones, Mark Kemp, Martin Stockley, Karl Gibson, Gavin Whitlock
  • 1-cyano-pyrrolidine compounds as USP30 inhibitors
    Patent number: 11066365
    Abstract: The present invention relates to novel compounds and method for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (II) or a pharmaceutically acceptable sat thereof, wherein R1, R2, R3, R4, R5, R8, R9, R10, R12, Z, Y and m are as defined herein.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: July 20, 2021
    Assignee: Mission Therapeutics Limited
    Inventors: Alison Jones, Mark Kemp, Martin Stockley, Karl Gibson, Gavin Whitlock
  • 1-cyano-pyrrolidine compounds as USP30 inhibitors
    Patent number: 11053198
    Abstract: The present invention relates to novel compounds and method for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (II) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R8, R9, R10, R12, Z, Y and m are as defined herein.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: July 6, 2021
    Assignee: MISSION THERAPEUTICS LIMITED
    Inventors: Alison Jones, Mark Kemp, Martin Stockley, Karl Gibson, Gavin Whitlock
  • 1-cyano-pyrrolidine compounds as USP30 inhibitors
    Patent number: 10689345
    Abstract: The present invention relates to novel compounds and method for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (II) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R8, R9, R10, R12, Z, Y and m are as defined herein.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: June 23, 2020
    Assignee: Mission Therapeutics Limited
    Inventors: Alison Jones, Mark Kemp, Martin Stockley, Karl Gibson, Gavin Whitlock
  • 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS
    Publication number: 20200181086
    Abstract: The present invention relates to novel compounds and method for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (II) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R8, R9, R10, Z, Y and m are as defined herein.
    Type: Application
    Filed: February 12, 2020
    Publication date: June 11, 2020
    Inventors: Alison Jones, Mark Kemp, Martin Stockley, Karl Gibson, Gavin Whitlock
  • 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS
    Publication number: 20190322624
    Abstract: The present invention relates to novel compounds and method for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (II) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R8, R9, R10, R12, Z, Y and m are as defined herein.
    Type: Application
    Filed: May 22, 2019
    Publication date: October 24, 2019
    Inventors: Alison Jones, Mark Kemp, Martin Stockley, Karl Gibson, Gavin Whitlock
  • 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS
    Publication number: 20190284138
    Abstract: The present invention relates to novel compounds and method for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (II) or a pharmaceutically acceptable sat thereof, wherein R1, R2, R3, R4, R5, R8, R9, R10, R12, Z, Y and m are as defined herein.
    Type: Application
    Filed: May 22, 2019
    Publication date: September 19, 2019
    Inventors: Alison Jones, Mark Kemp, Martin Stockley, Karl Gibson, Gavin Whitlock
  • 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS
    Publication number: 20190270708
    Abstract: The present invention relates to novel compounds and method for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (II) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R8, R9, R10, R12, Z, Y and m are as defined herein.
    Type: Application
    Filed: March 11, 2019
    Publication date: September 5, 2019
    Inventors: Alison Jones, Mark Kemp, Martin Stockley, Karl Gibson, Gavin Whitlock
  • 1-cyano-pyrrolidine compounds as USP30 inhibitors
    Patent number: 10343992
    Abstract: The present invention relates to novel compounds and method for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (II) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R8, R9, R10, R12, Z, Y and m are as defined herein.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: July 9, 2019
    Assignee: Missions Therapeutics Limited
    Inventors: Alison Jones, Mark Kemp, Martin Stockley, Karl Gibson, Gavin Whitlock